<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03816163</url>
  </required_header>
  <id_info>
    <org_study_id>8951-CL-5201</org_study_id>
    <secondary_id>2018-002551-15</secondary_id>
    <secondary_id>CTR20220914</secondary_id>
    <nct_id>NCT03816163</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma</brief_title>
  <official_title>A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab&#xD;
      in combination with Nab-P + GEM, determine overall survival and assess the safety and&#xD;
      tolerability of the combination treatment.&#xD;
&#xD;
      This study will also evaluate tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P&#xD;
      and GEM, and health-related quality of life (HRQoL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will have a safety lead in phase and a randomization phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT) - (safety lead in)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Incidence of dose limiting toxicities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>OS is defined as the time from the date of randomization until the date of death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Adverse Events (AEs)</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by incidence of serious adverse events (SAE)</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>Adverse Event (AE) is considered &quot;serious&quot; if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect, hospitalization, or medically important event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by incidence of treatment emergent adverse events (TEAE)</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>Treatment Emergent Adverse Event (TEAE) is defined as any AE which starts, or worsens, after the first dose of study drug through 30 days after the last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with laboratory value abnormalities and/or adverse events (AEs)</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>Number of participants with potentially clinically significant laboratory values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with vital sign abnormalities and /or adverse events (AEs)</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>Number of participants with potentially clinically significant vital sign values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with electrocardiograms (ECG) abnormalities and or adverse events</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>12-lead ECGs will be recorded. Prior to the ECG, participants should rest in supine position for 10 minutes. ECGs will be read and assessed locally.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse events</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>Number of participants with potentially clinically significant ECOG performance status values. ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>PFS is defined as the time from the date of randomization until the date of radiological progressive disease (PD) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 by investigator evaluation or death from any cause, whichever is earliest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>ORR is defined as the proportion of participants who have a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by investigator evaluation per RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-drug antibody (ADA) Positive Participants</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>Immunogenicity will be measured by the number of participants that are ADA positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>DCR is defined as the proportion of participants who have best overall response of stable disease, complete response (CR) or partial response (PR) as assessed by investigator evaluation per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Of Response (DOR)</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>DOR is defined as the time from the date of the first response (CR/PR) until the date of progressive disease as assessed by investigator evaluation per RECIST 1.1 or date of death from any cause, whichever is earliest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CA (Cancer Antigen) 19-9</measure>
    <time_frame>Baseline up to 65 months</time_frame>
    <description>Change from baseline in serum CA19-9 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of zolbetuximab: Concentration Immediately Prior to Dosing (Ctrough)</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>Ctrough will be derived from the PK serum samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Nab-P: Area Under the Concentration-time Curve from the Time of Dosing Extrapolated to Time Infinity (AUCinf)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>AUCinf will be derived from the PK plasma samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Nab-P: Area Under the Concentration-time Curve from the Time of Dosing Until the Last Measurable Concentration (AUClast)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>AUClast will be derived from the PK plasma samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Nab-P: Maximum Concentration (Cmax)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Cmax will be derived from the PK plasma samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Nab-P: Time of Maximum Concentration (Tmax)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Tmax will be derived from the PK plasma samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Nab-P: Terminal Elimination Half-life (T1/2)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>T1/2 will be derived from the PK plasma samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Nab-P: Clearance (CL)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>CL will be derived from the PK plasma samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Nab-P: Volume of Distribution During the Terminal Phase (Vz)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Vz will be derived from the PK plasma samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of gemcitabine: Area Under the Concentration-time Curve from the Time of Dosing Extrapolated to Time Infinity (AUCinf)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>AUCinf will be derived from the PK plasma samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of gemcitabine: Area Under the Concentration-time Curve from the Time of Dosing Until the Last Measurable Concentration (AUClast)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>AUClast will be derived from the PK plasma samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of gemcitabine: Maximum Concentration (Cmax)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Cmax will be derived from the PK plasma samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of gemcitabine: Time of Maximum Concentration (Tmax)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Tmax will be derived from the PK plasma samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of gemcitabine: Terminal Elimination Half-life (T1/2)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>T1/2 will be derived from the PK plasma samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of gemcitabine: Clearance (CL)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>CL will be derived from the PK plasma samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of gemcitabine: Volume of Distribution During the Terminal Phase (Vz)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Vz will be derived from the PK plasma samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQoL) measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC-QLQ-C30)</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Participants rate items on a four-point scale, with 1 as &quot;not at all&quot; and 4 as &quot;very much.&quot; For functional scales, higher scores indicate better functioning, while for symptom scales/items, higher scores indicate worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQoL) measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer Module (EORTC-QLQ-PAN-26)</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>EORTC-QLQ-PAN26 is a 26-item questionnaire that evaluates pancreatic cancer-specific symptoms such as pain, dietary changes, jaundice, altered bowel habits, and emotional problems. Participants rate items on a four-point scale, with 1 as &quot;not at all&quot; and 4 as &quot;very much.&quot; For symptom scales/items, higher scores indicate worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQoL) measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L)</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>The EQ-5D-5L is a standardized instrument for use as a measure of health outcome consisting of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale for health status.&#xD;
Each domain comprises 5 severity levels (no problems, slight problems, moderate problems, severe problems, extreme problems). The general visual analog scale records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQoL) measured by the Patient Global Impression of Change (PGIC) scale</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>The PGIC is a single-item questionnaire that asks participants to provide the overall self-assessment of change in their disease on a 7-point scale ranging from &quot;very much worse&quot; to &quot;very much better&quot; as compared to the participant starting the study treatment. Only PGIC questions assessing pain and overall status will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQoL) measured by the Patient Global Impression of Severity (PGIS) Scale</measure>
    <time_frame>Up to 65 months</time_frame>
    <description>The PGIS is a single-item questionnaire that asks participants to provide the overall self-assessment of their disease severity on a 4-point scale for the past week, with 1 as &quot;None&quot; and 4 as &quot;Severe&quot;. Only PGIS questions assessing pain and overall status will be collected.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">369</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Metastatic Pancreatic Cancer</condition>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>zolbetuximab +nab-paclitaxel + gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with zolbetuximab in combination with nab-paclitaxel and gemcitabine for the phase 1 portion of the study to establish the recommended dose of zolbetuximab for the phase 2 portion. In the phase 2 portion, the participants will be treated with zolbetuximab at dose determined by the phase 1 portion of the study in combination with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nab-paclitaxel + gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolbetuximab</intervention_name>
    <description>Administered as an intravenous infusion.</description>
    <arm_group_label>zolbetuximab +nab-paclitaxel + gemcitabine</arm_group_label>
    <other_name>IMAB362</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>Administered as an intravenous infusion</description>
    <arm_group_label>nab-paclitaxel + gemcitabine</arm_group_label>
    <arm_group_label>zolbetuximab +nab-paclitaxel + gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>Administered as an intravenous infusion</description>
    <arm_group_label>nab-paclitaxel + gemcitabine</arm_group_label>
    <arm_group_label>zolbetuximab +nab-paclitaxel + gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A female subject is eligible to participate if she is not pregnant or lactating and at&#xD;
             least 1 of the following conditions applies:&#xD;
&#xD;
               -  Not a woman of childbearing potential (WOCBP) OR&#xD;
&#xD;
               -  WOCBP who agrees to follow the contraceptive guidance throughout the treatment&#xD;
                  period and for at least 6 months after the final study drug administration.&#xD;
&#xD;
          -  Female subject must agree not to breastfeed starting at screening and throughout the&#xD;
             study period, and for 6 months after the final study drug administration.&#xD;
&#xD;
          -  Female subject must not donate ova starting at screening and throughout the study&#xD;
             period, and for 6 months after the final study drug administration.&#xD;
&#xD;
          -  A male subject with female partner(s) of child-bearing potential must agree to use&#xD;
             contraception during the treatment period and for at least 6 months after the final&#xD;
             study drug administration.&#xD;
&#xD;
          -  A male subject must not donate sperm during the treatment period and for at least 6&#xD;
             months after the final study drug administration.&#xD;
&#xD;
          -  Male subject with a pregnant or breastfeeding partner(s) must agree to remain&#xD;
             abstinent or use a condom for the duration of the pregnancy or time partner is&#xD;
             breastfeeding throughout the study period and for 6 months after the final study drug&#xD;
             administration.&#xD;
&#xD;
          -  Subject agrees not to participate in other interventional studies while receiving&#xD;
             study drug in present study.&#xD;
&#xD;
          -  Subject has histologically or cytologically confirmed adenocarcinoma of pancreas.&#xD;
&#xD;
          -  Subjects must have metastatic pancreatic adenocarcinoma that has not been previously&#xD;
             treated with chemotherapy.&#xD;
&#xD;
               -  Prior treatment with fluorouracil (5-FU) or GEM administered as a radiation&#xD;
                  sensitizer during and up to 4 weeks after radiation therapy is allowed&#xD;
&#xD;
               -  If a subject received adjuvant therapy, tumor recurrence or disease progression&#xD;
                  must have occurred at least 6 months after completing the last dose of the&#xD;
                  adjuvant therapy.&#xD;
&#xD;
               -  Subjects whose disease progressed on prior treatment with Nab-P and GEM are not&#xD;
                  eligible.&#xD;
&#xD;
          -  Subject has a measurable lesion(s) on at least 1 metastatic site based on RECIST 1.1&#xD;
             within 28 days prior to randomization. For subjects with only 1 measurable lesion and&#xD;
             prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must&#xD;
             have documented progression following radiation therapy.&#xD;
&#xD;
          -  Subject's tumor sample has CLDN18.2 expression in ≥ 75% of tumor cells demonstrating&#xD;
             moderate to strong membranous staining as determined by central immunohistochemistry&#xD;
             (IHC) testing&#xD;
&#xD;
          -  Subject has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Subject has predicted life expectancy ≥ 12 weeks.&#xD;
&#xD;
          -  Subject must meet all of the following criteria based on the laboratory tests that&#xD;
             will be collected within 14 days prior to randomization. In case of multiple&#xD;
             laboratory data within this period, the most recent data should be used.&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dl (no transfusion within 14 days of start of study treatment)&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
               -  Albumin ≥ 2.5 g/dL&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN&#xD;
                  without liver metastases (≤ 5 x ULN if liver metastases are present)&#xD;
&#xD;
               -  Estimated creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
               -  Prothrombin time/international normalized ratio (INR) and partial thromboplastin&#xD;
                  time ≤ 1.5 x ULN (except for subjects receiving anticoagulation therapy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has received other investigational treatment within 28 days prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Subject has received radiotherapy for metastatic pancreatic adenocarcinoma ≤ 14 days&#xD;
             prior to randomization and has not recovered from any related toxicity.&#xD;
&#xD;
          -  Subject has received systemic immunosuppressive therapy, including systemic&#xD;
             corticosteroids within 14 days prior to randomization. Subject using a physiologic&#xD;
             replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day&#xD;
             of hydrocortisone or up to 10 mg per day of prednisone), receiving a single dose of&#xD;
             systemic corticosteroids or receiving systemic corticosteroids as premedication for&#xD;
             radiologic imaging contrast use are allowed.&#xD;
&#xD;
          -  Subject has prior severe allergic reaction or intolerance to known ingredients of&#xD;
             zolbetuximab or other monoclonal antibody, including humanized or chimeric antibodies.&#xD;
&#xD;
          -  Subject has known immediate or delayed hypersensitivity, intolerance or&#xD;
             contraindication to any component of study treatment.&#xD;
&#xD;
          -  Subject has a known history of a positive test for human immunodeficiency virus&#xD;
             infection or known active hepatitis B (positive HBs antigen [Ag]) or hepatitis C&#xD;
             infection. NOTE: Screening for these infections should be conducted per local&#xD;
             requirements.&#xD;
&#xD;
               1. For subjects who are negative for HBs Ag, but hepatitis B core antibody positive,&#xD;
                  a hepatitis B virus DNA test will be performed and if positive, the subject will&#xD;
                  be excluded.&#xD;
&#xD;
               2. Subjects with positive hepatitis C serology but negative hepatitis C virus RNA&#xD;
                  test results are eligible.&#xD;
&#xD;
               3. Subjects treated for hepatitis C with undetectable viral load results are&#xD;
                  eligible.&#xD;
&#xD;
          -  Subject has a history of interstitial pneumonia or pulmonary fibrosis.&#xD;
&#xD;
          -  Subject has pleural effusion or ascites ≥ Grade 3.&#xD;
&#xD;
          -  Subject has an active autoimmune disease that has required systemic treatment in the&#xD;
             past 3 months prior to randomization.&#xD;
&#xD;
          -  Subject has active infection requiring systemic therapy that has not completely&#xD;
             resolved per investigator judgment within 7 days prior to randomization.&#xD;
&#xD;
          -  Subject has significant cardiovascular disease, including:&#xD;
&#xD;
               -  Congestive heart failure (defined as New York Heart Association Class III or IV),&#xD;
                  myocardial infarction, unstable angina, coronary angioplasty, coronary stenting,&#xD;
                  coronary artery bypass graft, cerebrovascular accident or hypertensive crisis&#xD;
                  within 6 months prior to randomization;&#xD;
&#xD;
               -  History of clinically significant ventricular arrhythmias (i.e., sustained&#xD;
                  ventricular tachycardia, ventricular fibrillation or Torsades de Pointes);&#xD;
&#xD;
               -  QTc interval &gt; 450 msec for male subjects; QTc interval &gt; 470 msec for female&#xD;
                  subjects;&#xD;
&#xD;
               -  Cardiac arrhythmias requiring anti-arrhythmic medications (Subjects with rate&#xD;
                  controlled atrial fibrillation for &gt; 1 month prior to randomization.)&#xD;
&#xD;
          -  Subject has a history of central nervous system metastases and/or carcinomatous&#xD;
             meningitis from pancreatic adenocarcinoma.&#xD;
&#xD;
          -  Subject has known peripheral sensory neuropathy ≥ Grade 2 unless the absence of deep&#xD;
             tendon reflexes is the sole neurological abnormality.&#xD;
&#xD;
          -  Subject has had a major surgical procedure ≤ 28 days prior to randomization.&#xD;
&#xD;
          -  Subject without complete recovery from a major surgical procedure ≤ 14 days prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Psychiatric illness or social situations that would preclude study compliance.&#xD;
&#xD;
          -  Subject has another malignancy for which treatment is required.&#xD;
&#xD;
          -  Subject has any concurrent disease, infection or co-morbid condition that interferes&#xD;
             with the ability of the subject to participate in the study, which places the subject&#xD;
             at undue risk or complicates the interpretation of data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Astellas Pharma Global Development</last_name>
    <phone>800-888-7704</phone>
    <email>astellas.registration@astellas.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Treatment Centers of Phoenix</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Medical Group</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hoag Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>TOI Clinical research</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midstate Medical Center</name>
      <address>
        <city>Meriden</city>
        <state>Connecticut</state>
        <zip>06451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynn Cancer Institute</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baptist Health</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of Atlanta</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America, Chicago</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>PMG Research of McFarland Clinic</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute (NCI)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Health System</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>David C Pratt Cancer Center</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwell Health Cancer Institute</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercy Clinic Oklahoma Communities, Inc</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America at Eastern Regional Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inova Dwight and Martha Schar</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MultiCare Regional Cancer Center - Gig Harbor</name>
      <address>
        <city>Gig Harbor</city>
        <state>Washington</state>
        <zip>98335</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vista Oncology</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Mason</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site AU61008</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>NSW 2250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site AU61007</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>HVGM+3C</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site AU61002</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site AU61005</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>5XRF+WX</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site AU61006</name>
      <address>
        <city>Warrnambool</city>
        <state>Victoria</state>
        <zip>VIC 3280</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site BR55003</name>
      <address>
        <city>Itajai</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site BR55002</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site BR55008</name>
      <address>
        <city>Rio Grande Do Sul</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site BR55004</name>
      <address>
        <city>Santa Catarina</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site BR55001</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site BR55006</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86001</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86008</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86014</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86026</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86009</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86004</name>
      <address>
        <city>Guangdong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86020</name>
      <address>
        <city>Guangdong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86016</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86012</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86002</name>
      <address>
        <city>Hubei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86005</name>
      <address>
        <city>Jiangsu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86011</name>
      <address>
        <city>Jiangsu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86025</name>
      <address>
        <city>Jiangsu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86024</name>
      <address>
        <city>Shan XI</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86023</name>
      <address>
        <city>Shandong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86006</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86013</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86019</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86017</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86007</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86022</name>
      <address>
        <city>Xinjiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86003</name>
      <address>
        <city>Zhejiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86018</name>
      <address>
        <city>Zhejiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CN86010</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33008</name>
      <address>
        <city>Besancon</city>
        <state>Besancon Cedex</state>
        <zip>6XG7+42</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33010</name>
      <address>
        <city>Brest</city>
        <state>Brest Cedex</state>
        <zip>9GV7+4G</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33004</name>
      <address>
        <city>Saint-Étienne</city>
        <state>Cedex 02</state>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site FR33015</name>
      <address>
        <city>Caen</city>
        <state>Cedex 5</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33006</name>
      <address>
        <city>Chambray</city>
        <state>Cedex 9</state>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33011</name>
      <address>
        <city>Dijon</city>
        <state>Dijon Cedex</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33012</name>
      <address>
        <city>Herblain</city>
        <state>Herblain Cedex</state>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33016</name>
      <address>
        <city>La Chaussee Saint Victor</city>
        <state>Loir-et-Cher</state>
        <zip>41260</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33009</name>
      <address>
        <city>Nancy</city>
        <state>Nancy Cedex</state>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33017</name>
      <address>
        <city>Rouen</city>
        <state>Normandy</state>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33003</name>
      <address>
        <city>Aquitaine</city>
        <state>Pessac</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33013</name>
      <address>
        <city>Villejuif</city>
        <state>Villejuif Cedex</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33001</name>
      <address>
        <city>Bayonne Cedex</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33018</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33002</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33020</name>
      <address>
        <city>Lyon Cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33021</name>
      <address>
        <city>Nice Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33023</name>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33014</name>
      <address>
        <city>Plerin</city>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33005</name>
      <address>
        <city>Pringy Cedex</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33019</name>
      <address>
        <city>Roche-Sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site FR33007</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site IR35301</name>
      <address>
        <city>Elm Park</city>
        <state>Dublin</state>
        <zip>D04 T6F4</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site IE35303</name>
      <address>
        <city>Cork</city>
        <zip>T12 DV56</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site IT39006</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site IT39004</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site IT39009</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site IT39015</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site IT39002</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site IT39012</name>
      <address>
        <city>Lazio</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site IT39010</name>
      <address>
        <city>Lombardia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site IT39003</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site IT39014</name>
      <address>
        <city>Toscana</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site IT39008</name>
      <address>
        <city>Veneto</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP81007</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP81001</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP81005</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP81006</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP81003</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP81008</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP81011</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP81012</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP81014</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP81013</name>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP81002</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP81015</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP81004</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP81010</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site JP81009</name>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site KR82005</name>
      <address>
        <city>Seongnam-Si</city>
        <state>Gyeonggi-do</state>
        <zip>013620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site KR82008</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site KR82010</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site KR82009</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site KR82011</name>
      <address>
        <city>Jeollanam-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site KR82001</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site KR82003</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site KR82004</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site KR82007</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site KR82002</name>
      <address>
        <city>Seoul</city>
        <zip>F3QP+76</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site KR82006</name>
      <address>
        <city>Seoul</city>
        <zip>G234+36</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site MX52004</name>
      <address>
        <city>Distrito Federal</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site MX52003</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site MX52005</name>
      <address>
        <city>Veracruz</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34004</name>
      <address>
        <city>Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34001</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>8208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34011</name>
      <address>
        <city>A Coruna</city>
        <state>Galicia</state>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site ES34003</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34010</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34013</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34007</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34018</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34021</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34014</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34025</name>
      <address>
        <city>Castello de la plana</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34002</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34005</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34015</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34016</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34006</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34009</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34012</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site ES34008</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34020</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34026</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34024</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site ES34017</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site TW88604</name>
      <address>
        <city>Tainan</city>
        <state>East District</state>
        <zip>70457</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site TW88606</name>
      <address>
        <city>Taoyuan</city>
        <state>Guishan District</state>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site TW88607</name>
      <address>
        <city>Tainan City</city>
        <state>Liuying District</state>
        <zip>73657</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site TW88608</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site TW88602</name>
      <address>
        <city>Taichung City</city>
        <zip>5M5J+36</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site TW88603</name>
      <address>
        <city>Tainan City</city>
        <zip>26CC+4Q</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site TW88605</name>
      <address>
        <city>Taipei City</city>
        <zip>2GR9+7H</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site TW88601</name>
      <address>
        <city>Taipei City</city>
        <zip>4G9C+W3</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site TW88609</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site TR90004</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site TR90006</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site TR90003</name>
      <address>
        <city>Diyarbakir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site TR90002</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site TR90005</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site TR90001</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>China</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2023</verification_date>
  <study_first_submitted>January 23, 2019</study_first_submitted>
  <study_first_submitted_qc>January 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>September 15, 2023</last_update_submitted>
  <last_update_submitted_qc>September 15, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic pancreatic cancer</keyword>
  <keyword>IMAB362</keyword>
  <keyword>nab-paclitaxel</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>zolbetuximab</keyword>
  <keyword>metastatic pancreatic adenocarcinoma</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>CLDN 18.2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03816163
org study id: 8951-CL-5201
secondary id: 2018-002551-15
secondary id: CTR20220914
nct id: NCT03816163
lead sponsor: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab
      in combination with Nab-P + GEM, determine overall survival and assess the safety and
      tolerability of the combination treatment.

      This study will also evaluate tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P
      and GEM, and health-related quality of life (HRQoL).
This study will have a safety lead in phase and a randomization phase.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Dose Limiting Toxicities (DLT) - (safety lead in)
time frame: Up to 28 days
description: Incidence of dose limiting toxicities.
measure: Overall Survival (OS)
time frame: Up to 65 months
description: OS is defined as the time from the date of randomization until the date of death from any cause.
measure: Safety assessed by Adverse Events (AEs)
time frame: Up to 65 months
description: An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.
measure: Safety assessed by incidence of serious adverse events (SAE)
time frame: Up to 65 months
description: Adverse Event (AE) is considered "serious" if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect, hospitalization, or medically important event.
measure: Safety assessed by incidence of treatment emergent adverse events (TEAE)
time frame: Up to 65 months
description: Treatment Emergent Adverse Event (TEAE) is defined as any AE which starts, or worsens, after the first dose of study drug through 30 days after the last dose of study drug.
measure: Number of participants with laboratory value abnormalities and/or adverse events (AEs)
time frame: Up to 65 months
description: Number of participants with potentially clinically significant laboratory values.
measure: Number of participants with vital sign abnormalities and /or adverse events (AEs)
time frame: Up to 65 months
description: Number of participants with potentially clinically significant vital sign values.
measure: Number of participants with electrocardiograms (ECG) abnormalities and or adverse events
time frame: Up to 65 months
description: 12-lead ECGs will be recorded. Prior to the ECG, participants should rest in supine position for 10 minutes. ECGs will be read and assessed locally.
measure: Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse events
time frame: Up to 65 months
description: Number of participants with potentially clinically significant ECOG performance status values. ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.
measure: Progression Free Survival (PFS)
time frame: Up to 65 months
description: PFS is defined as the time from the date of randomization until the date of radiological progressive disease (PD) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 by investigator evaluation or death from any cause, whichever is earliest.
measure: Objective Response Rate (ORR)
time frame: Up to 65 months
description: ORR is defined as the proportion of participants who have a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by investigator evaluation per RECIST 1.1.
measure: Number of anti-drug antibody (ADA) Positive Participants
time frame: Up to 65 months
description: Immunogenicity will be measured by the number of participants that are ADA positive.
measure: Disease Control Rate (DCR)
time frame: Up to 65 months
description: DCR is defined as the proportion of participants who have best overall response of stable disease, complete response (CR) or partial response (PR) as assessed by investigator evaluation per RECIST 1.1
measure: Duration Of Response (DOR)
time frame: Up to 65 months
description: DOR is defined as the time from the date of the first response (CR/PR) until the date of progressive disease as assessed by investigator evaluation per RECIST 1.1 or date of death from any cause, whichever is earliest.
measure: Change in CA (Cancer Antigen) 19-9
time frame: Baseline up to 65 months
description: Change from baseline in serum CA19-9 will be assessed.
measure: PK of zolbetuximab: Concentration Immediately Prior to Dosing (Ctrough)
time frame: Up to 65 months
description: Ctrough will be derived from the PK serum samples collected.
measure: PK of Nab-P: Area Under the Concentration-time Curve from the Time of Dosing Extrapolated to Time Infinity (AUCinf)
time frame: Up to 30 days
description: AUCinf will be derived from the PK plasma samples collected.
measure: PK of Nab-P: Area Under the Concentration-time Curve from the Time of Dosing Until the Last Measurable Concentration (AUClast)
time frame: Up to 30 days
description: AUClast will be derived from the PK plasma samples collected.
measure: PK of Nab-P: Maximum Concentration (Cmax)
time frame: Up to 30 days
description: Cmax will be derived from the PK plasma samples collected.
measure: PK of Nab-P: Time of Maximum Concentration (Tmax)
time frame: Up to 30 days
description: Tmax will be derived from the PK plasma samples collected.
measure: PK of Nab-P: Terminal Elimination Half-life (T1/2)
time frame: Up to 30 days
description: T1/2 will be derived from the PK plasma samples collected.
measure: PK of Nab-P: Clearance (CL)
time frame: Up to 30 days
description: CL will be derived from the PK plasma samples collected.
measure: PK of Nab-P: Volume of Distribution During the Terminal Phase (Vz)
time frame: Up to 30 days
description: Vz will be derived from the PK plasma samples collected.
measure: PK of gemcitabine: Area Under the Concentration-time Curve from the Time of Dosing Extrapolated to Time Infinity (AUCinf)
time frame: Up to 30 days
description: AUCinf will be derived from the PK plasma samples collected.
measure: PK of gemcitabine: Area Under the Concentration-time Curve from the Time of Dosing Until the Last Measurable Concentration (AUClast)
time frame: Up to 30 days
description: AUClast will be derived from the PK plasma samples collected.
measure: PK of gemcitabine: Maximum Concentration (Cmax)
time frame: Up to 30 days
description: Cmax will be derived from the PK plasma samples collected.
measure: PK of gemcitabine: Time of Maximum Concentration (Tmax)
time frame: Up to 30 days
description: Tmax will be derived from the PK plasma samples collected.
measure: PK of gemcitabine: Terminal Elimination Half-life (T1/2)
time frame: Up to 30 days
description: T1/2 will be derived from the PK plasma samples collected.
measure: PK of gemcitabine: Clearance (CL)
time frame: Up to 30 days
description: CL will be derived from the PK plasma samples collected.
measure: PK of gemcitabine: Volume of Distribution During the Terminal Phase (Vz)
time frame: Up to 30 days
description: Vz will be derived from the PK plasma samples collected.
measure: Health Related Quality of Life (HRQoL) measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC-QLQ-C30)
time frame: Up to 65 months
description: The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." For functional scales, higher scores indicate better functioning, while for symptom scales/items, higher scores indicate worse symptoms.
measure: Health Related Quality of Life (HRQoL) measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer Module (EORTC-QLQ-PAN-26)
time frame: Up to 65 months
description: EORTC-QLQ-PAN26 is a 26-item questionnaire that evaluates pancreatic cancer-specific symptoms such as pain, dietary changes, jaundice, altered bowel habits, and emotional problems. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." For symptom scales/items, higher scores indicate worse symptoms.
measure: Health Related Quality of Life (HRQoL) measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L)
time frame: Up to 65 months
description: The EQ-5D-5L is a standardized instrument for use as a measure of health outcome consisting of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale for health status.
Each domain comprises 5 severity levels (no problems, slight problems, moderate problems, severe problems, extreme problems). The general visual analog scale records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples.
measure: Health Related Quality of Life (HRQoL) measured by the Patient Global Impression of Change (PGIC) scale
time frame: Up to 65 months
description: The PGIC is a single-item questionnaire that asks participants to provide the overall self-assessment of change in their disease on a 7-point scale ranging from "very much worse" to "very much better" as compared to the participant starting the study treatment. Only PGIC questions assessing pain and overall status will be collected.
measure: Health Related Quality of Life (HRQoL) measured by the Patient Global Impression of Severity (PGIS) Scale
time frame: Up to 65 months
description: The PGIS is a single-item questionnaire that asks participants to provide the overall self-assessment of their disease severity on a 4-point scale for the past week, with 1 as "None" and 4 as "Severe". Only PGIS questions assessing pain and overall status will be collected.
arm group label: zolbetuximab +nab-paclitaxel + gemcitabine
arm group type: Experimental
description: Participants will be treated with zolbetuximab in combination with nab-paclitaxel and gemcitabine for the phase 1 portion of the study to establish the recommended dose of zolbetuximab for the phase 2 portion. In the phase 2 portion, the participants will be treated with zolbetuximab at dose determined by the phase 1 portion of the study in combination with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
arm group label: nab-paclitaxel + gemcitabine
arm group type: Active Comparator
description: Participants will be treated with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
intervention type: Drug
intervention name: zolbetuximab
description: Administered as an intravenous infusion.
arm group label: zolbetuximab +nab-paclitaxel + gemcitabine
other name: IMAB362
intervention type: Drug
intervention name: nab-paclitaxel
description: Administered as an intravenous infusion
arm group label: nab-paclitaxel + gemcitabine
arm group label: zolbetuximab +nab-paclitaxel + gemcitabine
intervention type: Drug
intervention name: gemcitabine
description: Administered as an intravenous infusion
arm group label: nab-paclitaxel + gemcitabine
arm group label: zolbetuximab +nab-paclitaxel + gemcitabine
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Medical Director
role: Study Director
affiliation: Astellas Pharma Global Development
last name: Astellas Pharma Global Development
phone: 800-888-7704
email: astellas.registration@astellas.com
facility: 
status: Withdrawn
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Withdrawn
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Completed
facility: 
status: Recruiting
facility: 
status: Withdrawn
facility: 
status: Withdrawn
facility: 
status: Withdrawn
facility: 
status: Recruiting
facility: 
status: Withdrawn
facility: 
status: Recruiting
facility: 
status: Withdrawn
facility: 
status: Completed
facility: 
status: Completed
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Completed
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Withdrawn
facility: 
status: Withdrawn
facility: 
status: Withdrawn
facility: 
status: Recruiting
facility: 
status: Withdrawn
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Withdrawn
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Withdrawn
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Completed
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Withdrawn
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Active, not recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Withdrawn
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Withdrawn
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Withdrawn
facility: 
status: Withdrawn
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
country: Australia
country: Brazil
country: China
country: France
country: Ireland
country: Italy
country: Japan
country: Korea, Republic of
country: Mexico
country: Spain
country: Taiwan
country: Turkey
country: United States
responsible party type: Sponsor
mesh term: Adenocarcinoma
mesh term: Pancreatic Neoplasms
mesh term: Paclitaxel
mesh term: Gemcitabine
sharing ipd: Yes
ipd description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
ipd info type: Study Protocol
ipd info type: Statistical Analysis Plan (SAP)
ipd info type: Clinical Study Report (CSR)
ipd time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
ipd access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
ipd url: https://www.clinicalstudydatarequest.com/